Abbott, P. J. Comfrey: avaliação do risco para a saúde em doses baixas. Med.J. Aust. 12-5-1988;149(11-12):678-682. Ver resumo.Investigation of pyrrolizidine alkaloids and their n-oxides in commercial comfrey containing products and botanical materials by liquid chromatography electrospray ionization mass spectrometry. J AOAC Int 2005; 88 (2):406-412. Ver resumo.Barthomeuf, C. M., Debiton, E., Barbakadze, V. V., and Kemertelidze, E. P., Evaluation of the dietetic and therapeutic potential of a high molecular weight hydroxycinnamate-derived polymer from Symphytum asperum Lepech. Relativamente às suas propriedades antioxidantes, anti-flipoperoxidantes, anti-inflamatórias e citotóxicas. J Agric.Food Chem 2001; 49 (8):3942-3946. Ver resumo.Dasgupta, A. Review of abnormal laboratory test results and toxic effects due to use of herbal medicines. Am J Clin Pathol 2003; 120 (1): 127-137. Ver resumo.Fijalkowski, D. and Seroczynska, M. Herba ol. 1977;23:47.Huxtable, R. J., Luthy, J., e Zweifel, U., Toxicidade das preparações de pepsina comfrey. N. Engl.J. Med. 10-23-1986;315(17):1095. Ver resumo.Larrey, D. Presse Med 4-16-1994; 23 (15):691-693. Ver resumo.Lewis, C. J. FDA aconselha os fabricantes de suplementos dietéticos a remover os produtos Comfrey do mercado. 7-6-2001;
Lin, C. C., Yang, C. C., Phua, D. H., Deng, J. F., and Lu, L. H. an outbreak of foxglove leaf poisoning. J Chin Med.Assoc. 2010;73(2):97-100. Ver resumo.
Mackinnon, M. Na prática geral, ‘sempre espere o inesperado’. Aust.Familia.Physician 2008; 37 (4):235-236. Ver resumo.Makarova, G. V., e et al. Fazenda.Zh. 1966;21(5):41.Mazzocchi, A. and Montanaro, F. Observational study of the use of Symphytum 5CH in the management of pain and tumefacting after dental implant surgery. Homeopatia. 2012;101(4):211-216. Ver resumo.New South Wales Health, Austrália. Alterações à lista de venenos. Venison Legislation Circular 3-22-1993; 60
Ramlau, J. . Ugeskr.Laeger 8-19-2002; 164(34):3979. Ver resumo.Ridker, P. N. e McDermont, W. V. Manha.J. Med. 1989;87(6):701. Ver resumo.Satake, M., Shokuhin Eiseigaku Zashi 2010; 51 (6):408-414. Ver resumo.Staiger, C. Comfrey: a clinical overview. Fitother.Res 2012; 26(10):1441-1448. Ver resumo.Stamford, I. F. And Tavares, I. A. the effect of an aqueous extract of comfrey on prostaglandin synthesis by rat isolated stomach. J Pharm Pharmacol 1983; 35 (12): 816-817. Ver resumo.Summers, R. S. Cardiotoxic principle in comfrey. S. Afr.Med J 1-13-1979; 55 (2): 37. Ver resumo.Tunon, H., Olavsdotter, C., and Bohlin, L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants., Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. J Ethnopharmacol 1995;48(2):61-76. View abstract.
Ulubelen, A. and Doganca, S. Anadoline, a new senecio alkaloid from symphytum orientale. Tetrahedron Lett 1970;30:2583-2585. View abstract.
Winship, K. A. Toxicity of comfrey. Adverse Drug React.Toxicol.Rev. 1991;10(1):47-59. View abstract.
Bach N, Thung SN, Schaffner F. Comfrey herb tea-induced heapatic veno-occlusive disesae. Am J Med 1989;87:97-9. View abstract.
Chojkier M., Síndrome de obstrução sinusoidal hepática: toxicidade dos alcalóides da pirrolizidina. J Hepatol 2003; 39:437-46. Ver resumo.Huxtable RJ, Awang DV. Envenenamento por pirrolizidina. Am J Med 1990; 89: 547-8.Koll R, Klingenburg S. Fortschr Med Orig 2002; 120: 1-9. Ver resumo.plantas medicinais contendo alcalóides de pirrolizidina na Europa. Pharmazie 1995; 50: 83-98.Stewart MJ, Steenkamp V. Pyrrolizidine poisoning: a neglected area in human toxicology. Ther Drug Monit 2001; 23: 698-708. Ver resumo.Stickel F, Seitz HK. A eficácia e segurança do comfrey., Public Health Nutr 2000; 3: 501-8. Ver resumo.